The FDA approved Moderna's RSV vaccine mRESVIA for expanded use in at-risk adults aged 18 to 59, enhancing preventive options against respiratory syncytial virus infections. Building on mRNA vaccine technology advancements from COVID-19, this approval helps address respiratory disease burden in younger adults, offering broader public health protection and signaling confidence in Moderna’s vaccine platform.